Rep. Sydney Kamlager-Dove (D-Calif.) urged the Drug Enforcement Administration (DEA) to refute any assertions that suggested rescheduling marijuana at the federal level would breach international treaty obligations.
In a letter to DEA administrator Anne Milgram, Kamlager-Dove stressed international treaties neither mandate the inclusion of marijuana in Schedule I or II of the Controlled Substance Act (CSA) nor preclude the DEA from embracing the Schedule III reclassification recommended by the U.S. Department of Health and Human Services (HHS) in August 2023.
“I write to urge you to reject any argument in support of maintaining marijuana in Schedule I or Schedule II based on U.S. Treaty obligations. Applicable Treaties neither require the U.S. to keep marijuana in Schedule I or II nor do they preclude the DEA from accepting HHS’s recommendation,” the congresswoman wrote in the letter to Milgram.
This call to action comes as the DEA conducts a comprehensive review of cannabis scheduling. Kamlager-Dove emphasized the critical need for transparency in the DEA’s discussions surrounding global drug policy agreements.
An advocate for full marijuana decriminalization, Kamlager-Dove advocated for the complete removal of cannabis from the CSA, acknowledging the historical significance of any movement toward this goal.
“Cannabis should be removed from the Controlled Substances Act (CSA) schedule entirely; however, I acknowledge that the rescheduling of cannabis is a historic…
